DUSP1 enhances the chemoresistance of gallbladder cancer via the modulation of the p38 pathway and DNA damage/repair system
Autor: | Qingren Lin, Zhimin Ye, Jun Fang, Yaping Xu, Maohui Yan, Zhun Wang, Juan Lin, Yuezhen Wang, Feiying Gu |
---|---|
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
inorganic chemicals Cancer Research Cell 03 medical and health sciences 0302 clinical medicine medicine Cytotoxicity neoplasms Cisplatin Oncogene business.industry Cancer Articles Cell cycle medicine.disease Molecular medicine female genital diseases and pregnancy complications 030104 developmental biology medicine.anatomical_structure Oncology Apoptosis 030220 oncology & carcinogenesis Cancer research business medicine.drug |
Zdroj: | Oncology letters. 16(2) |
ISSN: | 1792-1074 |
Popis: | Cisplatin (CDDP) is a commonly used drug for gallbladder cancer (GBC) chemotherapy. However, resistance to CDDP treatment results in relapse. Therefore, there is a need for the development of more effective treatment strategies to overcome chemoresistance. Dual-specificity phosphatase 1 (DUSP1) was reported to be involved in the resistance of a number of chemotherapeutic agents and was revealed to be highly expressed in CDDP-resistant GBC cells and CDDP-treated tumor types compared with normal cells or tissues in the present study. DUSP1 was revealed to inhibit the cytotoxicity of CDDP in two GBC cell lines, SGC996 and GBC-SD. P38 mitogen-activated protein kinases may be involved in the mechanism of chemoresistance. Furthermore, the number of DNA double-strand breaks in SGC996 OE cells was reduced compared with SGC996 vector cells indicating DUSP1 may attenuate the chemotherapeutic efficiency. Due to its potency against CDDP treatment, DUSP1 may be a promising target to overcome chemoresistance in GBC therapy. |
Databáze: | OpenAIRE |
Externí odkaz: |